Sequent Scientific Ltd's Q4FY25 Quarter Results
- 21 May 2025
Result Summary
- Sequent Scientific Ltd reported a 7.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 0.9%.
- Its expenses for the quarter were down by 7.8% QoQ and 9.5% YoY.
- The net profit decreased 80.4% QoQ and decreased 101.4% YoY.
- The earnings per share (EPS) of Sequent Scientific Ltd - at - during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 365.20 | 396.65 | 368.40 | -7.9% | -0.9% |
Total Expenses | 357.85 | 388.24 | 395.61 | -7.8% | -9.5% |
Profit Before Tax | 2.64 | 8.10 | -88.80 | -67.4% | -103.0% |
Tax | 1.36 | 1.62 | 3.64 | -16.0% | -62.6% |
Profit After Tax | 1.27 | 6.48 | -92.43 | -80.4% | -101.4% |
Earnings Per Share | 0.00 | 0.10 | -3.80 | -100.0% | -100.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sequent Scientific Ltd is a prominent player in the pharmaceutical industry, primarily focusing on animal health. The company offers a range of veterinary pharmaceutical products and is involved in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and formulations. Sequent Scientific Ltd operates globally, with a strong presence in various international markets, catering to the needs of animal healthcare. Recent developments in the company, if any, are not available in the provided data. The company's commitment to quality and innovation in the animal health sector positions it as a key entity within its industry.
Revenue
For the quarter ending Q4FY25, Sequent Scientific Ltd reported a total income of ₹365.20 crores. This reflects a decrease of 7.9% quarter-over-quarter (QoQ) from ₹396.65 crores in Q3FY25, and a marginal year-over-year (YoY) decrease of 0.9% from ₹368.40 crores in Q4FY24. The decline in total income both sequentially and annually highlights a trend that can be further explored for underlying factors. Despite the decrease, the revenue figures indicate a relatively stable performance when compared to the previous year's same quarter, with a slight downturn.
Profitability
The profitability metrics for Sequent Scientific Ltd show a significant decrease in profits for Q4FY25. The Profit Before Tax (PBT) was ₹2.64 crores, which is a notable drop of 67.4% QoQ from ₹8.10 crores in Q3FY25. Compared to Q4FY24's loss of ₹88.80 crores, there is a marked improvement YoY, although the figures still represent a challenging quarter. The Profit After Tax (PAT) was ₹1.27 crores in Q4FY25, down 80.4% from ₹6.48 crores in the previous quarter, yet a positive turnaround from a loss of ₹92.43 crores in Q4FY24. Earnings per Share (EPS) stood at ₹0.00, reflecting a 100% decline both QoQ and YoY, from ₹0.10 in Q3FY25 and -₹3.80 in Q4FY24, respectively. These figures highlight significant fluctuations in profitability over the periods analyzed.
Operating Metrics
The total expenses for Q4FY25 were reported at ₹357.85 crores, showing a decrease of 7.8% QoQ from ₹388.24 crores in Q3FY25, and a 9.5% decrease YoY from ₹395.61 crores in Q4FY24. This reduction in expenses suggests a measure of cost control or operational adjustments during the quarter. The tax expense for Q4FY25 was ₹1.36 crores, a decline of 16.0% QoQ from ₹1.62 crores in the previous quarter, and a 62.6% decrease YoY from ₹3.64 crores in Q4FY24. These metrics indicate changes in the company's operational efficiency and tax obligations over the periods analyzed. The variations in expenses and tax liability are key aspects that would be of interest for further operational analysis.